[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365820-105":59,"doc-detail-365820-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","advancing-antibodydrug-conjugates-precision-oncology-approaches-for-breast-and-pancreatic-cancers","Advancing Antibody–Drug Conjugates: Precision Oncology Approaches for Breast and Pancreatic Cancers","","An antibody–drug conjugate (ADC) integrates potent cytotoxic payloads with the specificity of monoclonal antibodies, enabling targeted cancer therapy. This review evaluates recent ADC developments and ongoing challenges, emphasizing how payload selection, linker technologies, antibody engineering, and ADC internalization influence outcomes in pancreatic ductal adenocarcinoma (PDAC) and triple-negative breast cancer (TNBC). TNBC ADCs show improved progression-free survival, while PDAC faces barriers such as low antigen density and limited internalization.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advancing-antibodydrug-conjugates-precision-oncology-approaches-for-breast-and-pancreatic-cancers/365820/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advancing-antibodydrug-conjugates-precision-oncology-approaches-for-breast-and-pancreatic-cancers/365820.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn Holloway","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is an antibody–drug conjugate (ADC) and why is it important in cancer therapy?","Question",{"text":112,"@type":113},"An ADC combines a targeted monoclonal antibody with a cytotoxic payload, aiming to deliver chemotherapy-like effects with improved specificity. It supports a precision approach to treating cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do ADC outcomes differ between triple-negative breast cancer (TNBC) and pancreatic ductal adenocarcinoma (PDAC)?",{"text":117,"@type":113},"In TNBC, ADCs such as sacituzumab govitecan and trastuzumab deruxtecan show improved progression-free survival in advanced disease. In PDAC, low antigen density and poor internalization limit clinical efficacy and regulatory success.",{"name":119,"@type":110,"acceptedAnswer":120},"Which ADC components does the review highlight as key factors for performance?",{"text":121,"@type":113},"The review focuses on payload improvements, linker technologies, antibody engineering, and ADC internalization. These elements are assessed for their roles in shaping effectiveness in PDAC and TNBC.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},365820,1790198748,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336474466712,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Review  \nAdvancing Antibody–Drug Conjugates: Precision Oncology Approaches for Breast and Pancreatic Cancers  \nDhanvin R. Yajaman 1,2, Youngman Oh 1,2, Jose G. Trevino 2,3 and J. Chuck Harrell 1,2, *  \nAcademic Editors: Ewa Krawczyk and Paula Dobosz  \nReceived: 17 April 2025  \nRevised: 23 May 2025  \nAccepted: 26 May 2025  \nPublished: 27 May 2025  \nCitation: Yajaman, D.R.; Oh, Y.; Trevino, J.G.; Harrell, J.C. Advancing Antibody–Drug Conjugates: Precision Oncology Approaches for Breast and Pancreatic Cancers. Cancers 2025, 17, 1792. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)cancers17111792  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Department of Pathology, Virginia Commonwealth University, Richmond, VA 23284, USA; [yajamandr@vcu.edu](yajamandr@vcu.edu) (D.R.Y.); [youngman.oh@vcuhealth.org](youngman.oh@vcuhealth.org) (Y.O.)  \n2 Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA 23284, USA; [jose.trevino@vcuhealth.org](jose.trevino@vcuhealth.org)  \n3 Department of Surgery, Virginia Commonwealth University, Richmond, VA 23284, USA  \n* [Correspondence: joshua.harrell@vcuhealth.org](Correspondence: joshua.harrell@vcuhealth.org)  \nSimple Summary: An antibody–drug conjugate (ADC) is a cancer-inhibiting therapeutic agent that combines compounds, such as chemotherapy, with a targeted antibody. In recent years, the development and launch of new ADCs have been conducted for breast and pancreatic cancers. This article discusses ADC properties while comparing different targets, linkers, and payloads effectively used to treat these aggressive cancer types.  \nAbstract: Background/Objectives: ADCs bring an innovative strategy to cancer treatment by conjugating powerful cytotoxic agents to the specificity of monoclonal antibodies. This review discusses recent advancements and challenges in the field of ADCs, along with future potential applications. Methods: Studies focused on the development of ADCs were reviewed. These include the effects of payload improvements, linker technologies, antibody engineering, and ADC internalization, which were particular topics of examination regarding their role in pancreatic ductal adenocarcinoma (PDAC) and triple-negative breast cancer (TNBC) . The efficacy of some ADCs for pancreatic and breast cancers was compared. Results: In TNBC, ADCs such as sacituzumab govitecan and trastuzumab deruxtecan have improved progression-free survival in advanced cases. In contrast, PDACADC development is challenged by low antigen density and poor internalization; despite evidence of target engagement in early trials targeting mesothelin and MUC1, ADCs for PDAC have yet to achieve significant clinical efficacy or regulatory approval. Conclusions: While ADCs have significantly advanced treatment options in TNBC, PDAC remains a difficult target due to its stroma-rich microenvironment and lack of high-density, tumorspecific antigens. This article emphasizes the need for tailor-made ADC designs to enhance results in various types of cancers and provides valuable insight into future advancementsin precision oncology.  \nKeywords: antibody–drug conjugates (ADCs); triple-negative breast cancer (TNBC); pancreatic ductal adenocarcinoma (PDAC); cancer biomarkers; targeted cancer therapy; monoclonal antibodies; precision oncology  \n1. Introduction  \n1.1. Overview of Cancer  \nIn 2020, an estimated 10 million people died from cancer globally, while nearly 600,000 cancer-related deaths were reported in the United States alone [1–3] . The lifetime probability of developing cancer is approximately 41.6% for men and 39.6% for  \nwomen in the U.S., meaning nearly 4 in 10 men and wom","cbCaikw6yxv1sBFY","https://ap.wps.com/l/cbCaikw6yxv1sBFY","pdf",2632857,28,"English","# Review\n## Abstract\n## Keywords\n## 1. Introduction\n### 1.1. Overview of Cancer\n### 1.2. Pancreatic Cancer","[{\"question\":\"What is an antibody–drug conjugate (ADC) and why is it important in cancer therapy?\",\"answer\":\"An ADC combines a targeted monoclonal antibody with a cytotoxic payload, aiming to deliver chemotherapy-like effects with improved specificity. It supports a precision approach to treating cancer.\"},{\"question\":\"How do ADC outcomes differ between triple-negative breast cancer (TNBC) and pancreatic ductal adenocarcinoma (PDAC)?\",\"answer\":\"In TNBC, ADCs such as sacituzumab govitecan and trastuzumab deruxtecan show improved progression-free survival in advanced disease. In PDAC, low antigen density and poor internalization limit clinical efficacy and regulatory success.\"},{\"question\":\"Which ADC components does the review highlight as key factors for performance?\",\"answer\":\"The review focuses on payload improvements, linker technologies, antibody engineering, and ADC internalization. These elements are assessed for their roles in shaping effectiveness in PDAC and TNBC.\"}]","Advancing Antibody–Drug Conjugates: Precision Oncology Approaches for Breast and Pancreatic Cancers | PDF",1790162492,71,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c99c9bf9e7bf4d13b0907d514b901d9.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9ba053d3a2d1c15fb0a9c49ff0345e28.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e704236c0aee2d6faaf78368d4e2a468.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/987fbfaade11283c94b15b9a71c21187.webp",980,1385]